Blood protein markers of Neocortical Amyloid-beta Burden: A candidate study using SOMAscan technology
Manuscript Number:
15-0020R1
Author(s):
David Baker, Chantal Bazenet, Samantha C. Burnham, Antonia Covin, Richard Dobson, Steven J. Kiddle, Simon Lovestone, Dipen P. Sangurdekar, Cristina A. Tan Hehir, Nicola Voyle, Zhanpan Zhang
Disclosures
David Baker
Sponsors:
Janssen R&D
Chantal Bazenet
Nothing to Disclose
Samantha C. Burnham
Patents/Royalties
Method for detection of a neurological disease
US 20140086836 A1
ABSTRACT
The present invention provides methods for predicting whether a subject will develop a disease capable of affecting cognitive function. More specifically, the present invention relates to the predictive detection of neurological diseases in a subject. The methods and systems provided enable a quantitative assessment and theoretical predictions of neocortical amyloid loading or amyloid beta levels based on the measurement of biomarkers in biological fluids that will provide an indication of whether a subject is likely to develop a neurological disease, such as Alzheimer's disease (AD).
Antonia Covin
Equity:
I work for Janssen and Janssen was the Sponsor of the study.
Sponsors:
I work for Janssen who sponsored this study
Richard Dobson
Grants
Agency:
Ely Lilly
Dates:
dec 14 for 2 yers
Steven J. Kiddle
Nothing to Disclose
Simon Lovestone
Lecture Fees:
Speaker fees for the Lundbeck Neuroscience Foundation series (less than £1000)
Patents/Royalties
Named as inventor on patents on biomarkers pertaining to Alzheimer's disease registered by Proteome Sciences and King's College London.
Grants
Agency:
Astra Zeneca and MRC
Dates:
2012-2016
Agency:
EU and multiple commercial entities (EMIF and EPAD IMI programmes)
Dates:
2012-2020
Dipen P. Sangurdekar
Sponsors:
Employed at General Electric and worked as biostatistician on the project